title: Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study.
abstract: We attempted to show a dose effect relationship for radiation therapy by treating patients harbouring malignant glioma with increasing doses of radiation in a step-wise fashion. We postulated that no increase in delayed toxicity would be seen because we used hyperfractionation technique. Between January 1981 and December 1988 we treated 280 patients three times daily at 4 hour intervals. 100 patients received a total dose of 6141 cGy, 73 patients received 7120 cGy, and 107 patients received 8000 cGy. CCNU was given at the time of tumor progression following radiotherapy. Median time to tumor progression was 28 weeks for patients who received 6141 cGy, 27 weeks for patients who received 7120 cGy and 36 weeks for patients who received 8000 cGy. Median survival was 46 weeks for patients who received 6141 cGy, 38 weeks for patients who received 7120 cGy and 45 weeks for patients who received 8000 cGy. There was no statistically significant difference in either time to tumor progression or survival among the three treatment arms and no dose response effect was seen. There was no increase in delayed radiation toxicity when the total radiation dose was increased up to 8000 cGy.
authors.affiliation: Department of Radiation Oncology, University of Alberta, Canada.
authors.forename: D S
authors.initials: DS
authors.lastname: Fulton
authors.forename: R C
authors.initials: RC
authors.lastname: Urtasun
authors.forename: I
authors.initials: I
authors.lastname: Scott-Brown
authors.forename: E S
authors.initials: ES
authors.lastname: Johnson
authors.forename: B
authors.initials: B
authors.lastname: Mielke
authors.forename: B
authors.initials: B
authors.lastname: Curry
authors.forename: D
authors.initials: D
authors.lastname: Huyser-Wierenga
authors.forename: J
authors.initials: J
authors.lastname: Hanson
authors.forename: M
authors.initials: M
authors.lastname: Feldstein
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D001254:Astrocytoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D001921:Brain / Q000473:pathology / Q000528:radiation effects; D001932:Brain Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D003037:Cobalt Radioisotopes / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016371:Cranial Irradiation / Q000009:adverse effects / Q000379:methods*; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D008920:Misonidazole / Q000627:therapeutic use; D015999:Multivariate Analysis; D009336:Necrosis; D016016:Proportional Hazards Models; D011832:Radiation Injuries / Q000209:etiology; D011867:Radioisotope Teletherapy / Q000009:adverse effects / Q000379:methods*; D011879:Radiotherapy Dosage; D012720:Severity of Illness Index; D012871:Skin Diseases / Q000209:etiology; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D003037:Cobalt Radioisotopes; D008130:Lomustine; D008920:Misonidazole